Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives $16.56 Average PT from Brokerages

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has received an average rating of “Buy” from the ten brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have given a buy rating and three have issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $16.5556.

A number of research analysts recently commented on the stock. Wall Street Zen downgraded shares of Inventiva from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Truist Financial assumed coverage on shares of Inventiva in a research report on Thursday, March 19th. They set a “buy” rating and a $13.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st.

Inventiva Stock Performance

Shares of NASDAQ:IVA opened at $3.55 on Tuesday. Inventiva has a 52 week low of $2.85 and a 52 week high of $7.98. The firm has a 50 day simple moving average of $4.65 and a 200 day simple moving average of $5.34.

Inventiva (NASDAQ:IVA) last issued its quarterly earnings results on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The company had revenue of $0.01 million for the quarter. As a group, analysts expect that Inventiva will post -0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IVA. Paradigm Biocapital Advisors LP purchased a new position in Inventiva during the fourth quarter valued at approximately $18,600,000. ADAR1 Capital Management LLC bought a new stake in Inventiva in the fourth quarter worth approximately $12,601,000. UBS Group AG grew its position in Inventiva by 28,881.6% in the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after acquiring an additional 2,634,580 shares in the last quarter. SymBiosis Capital Partners LLC bought a new stake in Inventiva in the fourth quarter worth approximately $12,090,000. Finally, Millennium Management LLC grew its position in Inventiva by 2,267.7% in the fourth quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock worth $12,334,000 after acquiring an additional 2,540,540 shares in the last quarter. 19.06% of the stock is owned by hedge funds and other institutional investors.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.